Major advances in cancer therapy have resulted in an unprecedented improvement in
patient survival for many cancers. Partially as a consequence of increased longevity, it has …

Cancer therapeutics-related cardiac dysfunction (CTRCD) has emerged as a major cause of
morbidity and mortality in cancer survivors. Effective clinical management of CTRCD is …

Cardiotoxic manifestation associated with breast cancer treatment by anthracycline regimen
increases patients' susceptibility to myocardial injury, reduction in left ventricular ejection …

The prognosis of cancer treatment depends on, among other aspects, the cardiotoxicity of
chemotherapy. This research aims to create a feasible algorithm for the early diagnosis of …

Background Trastuzumab is a drug used in HER2-positive breast cancer that increases
patient survival. Due to cardiotoxicity is the most important side effect of trastuzumab …

Background Myocardial infarction is the most common cause of heart failure. MI has been
intricately linked to ventricular remodeling, subsequently leading to the reduction in the …

Survivorship issues and treatment related toxicities have considerably increased in breast
cancer patients following improved therapeutic options. Cardiotoxicity has been a major …

Background Patients with multiple myeloma (MM) are at risk of cardiovascular events
(CVEs) as a result of disease burden–and treatment-related risk factors. Cardiac biomarkers …

BACKGROUND The anthracycline chemotherapeutic drugs are cardiotoxic. Studies have
found some indicators related to cardiotoxicity. However, there is currently no accurate …

Знание патогенеза и основных факторов риска кардиотоксичности антрациклиновыми
антибиотиками (АА) позволило разработать различные методики, направленные на …